Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model.
Lau SP, van Montfoort N, Kinderman P, Lukkes M, Klaase L, van Nimwegen M, van Gulijk M, Dumas J, Mustafa DAM, Lievense SLA, Groeneveldt C, Stadhouders R, Li Y, Stubbs A, Marijt KA, Vroman H, van der Burg SH, Aerts J, van Hall T, Dammeijer F, van Eijck CHJ. Lau SP, et al. Among authors: kinderman p. J Immunother Cancer. 2020 Jul;8(2):e000772. doi: 10.1136/jitc-2020-000772. J Immunother Cancer. 2020. PMID: 32690771 Free PMC article.
Arming oncolytic reovirus with GM-CSF gene to enhance immunity.
Kemp V, van den Wollenberg DJM, Camps MGM, van Hall T, Kinderman P, Pronk-van Montfoort N, Hoeben RC. Kemp V, et al. Among authors: kinderman p. Cancer Gene Ther. 2019 Sep;26(9-10):268-281. doi: 10.1038/s41417-018-0063-9. Epub 2018 Nov 23. Cancer Gene Ther. 2019. PMID: 30467340
Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
Groeneveldt C, Kinderman P, van den Wollenberg DJM, van den Oever RL, Middelburg J, Mustafa DAM, Hoeben RC, van der Burg SH, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: kinderman p. J Immunother Cancer. 2020 Oct;8(2):e001191. doi: 10.1136/jitc-2020-001191. J Immunother Cancer. 2020. PMID: 33082167 Free PMC article.
Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy.
Groeneveldt C, Kinderman P, van Stigt Thans JJC, Labrie C, Griffioen L, Sluijter M, van den Wollenberg DJM, Hoeben RC, den Haan JMM, van der Burg SH, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: kinderman p. J Immunother Cancer. 2022 Jul;10(7):e004464. doi: 10.1136/jitc-2021-004464. J Immunother Cancer. 2022. PMID: 35853671 Free PMC article.
Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy.
Groeneveldt C, van Ginkel JQ, Kinderman P, Sluijter M, Griffioen L, Labrie C, van den Wollenberg DJM, Hoeben RC, van der Burg SH, Ten Dijke P, Hawinkels LJAC, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: kinderman p. Cancer Res Commun. 2023 Feb 23;3(2):325-337. doi: 10.1158/2767-9764.CRC-23-0019. eCollection 2023 Feb. Cancer Res Commun. 2023. PMID: 36860656 Free PMC article.
Socs1-knockout in skin-resident CD4+ T cells in a protracted contact-allergic reaction results in an autonomous skin inflammation with features of early-stage mycosis fungoides.
Luo Y, Vermeer MH, de Haan S, Kinderman P, de Gruijl FR, van Hall T, Tensen CP. Luo Y, et al. Among authors: kinderman p. Biochem Biophys Rep. 2023 Aug 22;35:101535. doi: 10.1016/j.bbrep.2023.101535. eCollection 2023 Sep. Biochem Biophys Rep. 2023. PMID: 37664523 Free PMC article.
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.
Groeneveldt C, Kinderman P, Griffioen L, Rensing O, Labrie C, van den Wollenberg DJM, Hoeben RC, Coffey M, Loghmani H, Verdegaal EME, Welters MJP, van der Burg SH, van Hall T, van Montfoort N. Groeneveldt C, et al. Among authors: kinderman p. Cancer Immunol Res. 2024 Mar 4;12(3):334-349. doi: 10.1158/2326-6066.CIR-23-0480. Cancer Immunol Res. 2024. PMID: 38194598 Free PMC article.
Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.
Kurmasheva N, Said A, Wong B, Kinderman P, Han X, Rahimic AHF, Kress A, Carter-Timofte ME, Holm E, van der Horst D, Kollmann CF, Liu Z, Wang C, Hoang HD, Kovalenko E, Chrysopoulou M, Twayana KS, Ottosen RN, Svenningsen EB, Begnini F, Kiib AE, Kromm FEH, Weiss HJ, Di Carlo D, Muscolini M, Higgins M, van der Heijden M, Arulanandam R, Bardoul A, Tong T, Ozsvar A, Hou WH, Schack VR, Holm CK, Zheng Y, Ruzek M, Kalucka J, de la Vega L, Elgaher WAM, Korshoej AR, Lin R, Hiscott J, Poulsen TB, O'Neill LA, Roy DG, Rinschen MM, van Montfoort N, Diallo JS, Farin HF, Alain T, Olagnier D. Kurmasheva N, et al. Among authors: kinderman p. Nat Commun. 2024 May 15;15(1):4096. doi: 10.1038/s41467-024-48422-x. Nat Commun. 2024. PMID: 38750019 Free PMC article.
Author Correction: Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways.
Kurmasheva N, Said A, Wong B, Kinderman P, Han X, Rahimic AHF, Kress A, Carter-Timofte ME, Holm E, van der Horst D, Kollmann CF, Liu Z, Wang C, Hoang HD, Kovalenko E, Chrysopoulou M, Twayana KS, Ottosen RN, Svenningsen EB, Begnini F, Kiib AE, Kromm FEH, Weiss HJ, Di Carlo D, Muscolini M, Higgins M, van der Heijden M, Arulanandam R, Bardoul A, Tong T, Ozsvar A, Hou WH, Schack VR, Holm CK, Zheng Y, Ruzek M, Kalucka J, de la Vega L, Elgaher WAM, Korshoej AR, Lin R, Hiscott J, Poulsen TB, O'Neill LA, Roy DG, Rinschen MM, van Montfoort N, Diallo JS, Farin HF, Alain T, Olagnier D. Kurmasheva N, et al. Among authors: kinderman p. Nat Commun. 2024 Dec 19;15(1):10698. doi: 10.1038/s41467-024-55044-w. Nat Commun. 2024. PMID: 39702301 Free PMC article. No abstract available.
95 results